Biogen ( BIIB )

Share Interview Share Compensation

$235M Part D

Peak9.0yr

Flagship MS product accounting for 30% of company revenue; represents core franchise but faces generic erosion in 2035.

Help build intelligence for Biogen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified portfolio across neuroscience, rare disease, and immunology with 20+ active clinical programs including Phase 3 candidates in MS and stroke indication expansion

Strong R&D commitment at 25% intensity ($2.4B FY 2025) supporting emerging modalities including ASOs and rare disease therapeutics like SPINRAZA and SKYCLARYS

Watch Out For

Significant patent cliff exposure: TECFIDERA LOE 2035, VUMERITY LOE 2033, AVONEX and REBIF approaching LOE with no disclosed replacement revenue, creating restructuring pressure
Recent organizational instability with four major layoff events since 2023 totaling 2,000+ employees across Cambridge, RTP, and TN sites following Aduhelm withdrawal and strategic pivots

Generated by Claude from Biogen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

VUMERITY

$152M Part D

Peak6.9yr

Next-generation fumarate derivative designed to improve tolerability; LOE approaching 2033 accelerates pipeline dependency.

AVONEX

$139M Part D

LOE Approaching

Legacy biologic with approaching loss of exclusivity; biosimilar competition likely imminent.

REBIF

$131M Part D

LOE Approaching

Another interferon beta product facing biosimilar pressure; combined AVONEX/REBIF erosion threatens revenue base.

SKYCLARYS

Friedreich's ataxia

$45M Part D

Peak6.4yr

Recent rare disease approval (2023) representing portfolio diversification away from MS; early-stage peak-lifecycle revenue.

TYSABRI

$40M Part D

LOE Approaching

Monoclonal antibody approaching patent expiration; pipeline includes Phase 2/3 expansion into stroke and SPMS.

DIMETHYL FUMARATE

$12M Part D

Post-LOE

Post-LOE generic version of TECFIDERA; residual revenue reflects residual branded market share erosion.

DIMETHYL FUMARATE

$12M Part D

Post-LOE

Post-LOE generic version of TECFIDERA; residual revenue reflects residual branded market share erosion.

DIMETHYL FUMARATE

$8M Part D

Post-LOE

Post-LOE generic version; minimal residual revenue signals completion of TECFIDERA generic conversion.

SPINRAZA

Spinal muscular atrophy

$3M Part D

Peak9.3yr

Antisense oligonucleotide in rare neuromuscular disease; pioneering ASO platform with LOE 2036 provides near-term patent protection.

Pipeline & Clinical Trials

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Optic Neuritis

N/A

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multipl

Exercise

N/A

Clinical Trials (1)

NCT01065090A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis

N/A

Avonex® monotherapy

N/A

Clinical Trials (1)

NCT00463710Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

N/A

Natural History of the Progression of Choroideremia Study

Choroideremia

N/A

Clinical Trials (1)

NCT03359551Natural History of the Progression of Choroideremia Study

N/A

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cogniti

Relapsing-Remitting Multiple Sclerosis (RRMS)

N/A

Clinical Trials (1)

NCT02283918Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

N/A

MS PATHS Normative Sub-Study

Healthy Volunteer

N/A

Clinical Trials (1)

NCT02996084MS PATHS Normative Sub-Study

N/A

Omaveloxolone

Friedreich Ataxia

N/A

Clinical Trials (1)

NCT06628687A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

N/A

Natalizumab

N/A

Clinical Trials (1)

NCT05304520A Study for Tysabri Participant Preference

N/A

Konectom platform

Multiple Sclerosis (MS)

N/A

Clinical Trials (1)

NCT05106465A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

N/A

natalizumab

N/A

Clinical Trials (1)

NCT02386566Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

N/A

Biopsy

Mild Cognitive Impairment

N/A

Clinical Trials (1)

NCT02422407A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

N/A

Outpatient Muscle Biopsy

Sarcopenia

N/A

Clinical Trials (1)

NCT02839460A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy

N/A

Skin Taping

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT02125695Pilot Tape Harvesting Study

N/A

An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguis

N/A

Clinical Trials (1)

NCT05058950An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging

N/A

Multicenter Observational Study of Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

N/A

Clinical Trials (1)

NCT02308657Multicenter Observational Study of Myotonic Dystrophy Type 1

N/A

Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Va

Multiple Sclerosis (MS)

N/A

Clinical Trials (1)

NCT05197699Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

ThecaFlex DRx System

Spinal Muscular Atrophy

N/A

Clinical Trials (1)

NCT05866419Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

N/A

peginterferon beta-1a

Relapsing Forms of Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02230969Plegridy Observational Program

N/A

Multiple Sclerosis Performance Test

N/A

Clinical Trials (1)

NCT03926637Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

N/A

DigiCog

N/A

Clinical Trials (1)

NCT04756700Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis

N/A

Dimethyl fumarate

Multiple Sclerosis, Relapsing-Remitting

N/A

Clinical Trials (1)

NCT01911767Biogen Multiple Sclerosis Pregnancy Exposure Registry

N/A

SC Peginterferon beta-1a

N/A

Clinical Trials (1)

NCT03347370A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

N/A

Colonoscopy

N/A

Evaluation of Brain Atrophy in CIS Patients on Avonex

N/A

Clinical Trials (1)

NCT01592474Evaluation of Brain Atrophy in CIS Patients on Avonex

N/A

TruBeet inorganic beetroot juice

Nitrate

N/A

Clinical Trials (1)

NCT06602921The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function.

N/A

Functional MRI in Lupus Nephritis

N/A

Clinical Trials (1)

NCT01731054Functional MRI in Lupus Nephritis

N/A

This is a registry.

Dementia Disorder

N/A

natalizumab

Spinocerebellar Ataxia Type 2

N/A

Clinical Trials (1)

NCT02137109Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

N/A

Lumbar puncture

N/A

Clinical Trials (1)

NCT04288128Integrated Functional Evaluation of the Cerebellum

N/A

No Intervention

Choroideremia

N/A

Clinical Trials (4)

NCT04750785A Study to Assess Choroideremia (CHM) Health Outcomes

N/A

NCT04795206Natural Disease Progression in Participants With Choroideremia

N/A

MR Imaging

N/A

Clinical Trials (1)

NCT03218111Glymphatic Kinetics In Healthy Adult Volunteers

N/A

Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic

Myotonic Dystrophy 1

N/A

Clinical Trials (1)

NCT06089018Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy

N/A

dimethyl fumarate

N/A

Clinical Trials (1)

NCT02047097Dimethyl Fumarate (DMF) Observational Study

N/A

Assessments

Frontotemporal Dementia

N/A

Clinical Trials (2)

NCT03088956Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

N/A

NCT04926129Natural History of the Progression of X-Linked Retinitis Pigmentosa

N/A

Scan-Rescan Sub-Study of MS PATHS

N/A

Clinical Trials (1)

NCT04123353Scan-Rescan Sub-Study of MS PATHS

N/A

Systemic Sclerosis Clinical and Biomarker Study

N/A

Clinical Trials (1)

NCT02531009Systemic Sclerosis Clinical and Biomarker Study

N/A

Tysabri®

Mild Cognitive Impairment

N/A

Clinical Trials (1)

NCT01070823JC-Virus (JCV) Antibody Program

N/A

Adult Spinal Muscular Atrophy (SMA) China Registry

Muscular Atrophy, Spinal

N/A

Clinical Trials (1)

NCT05618379Adult Spinal Muscular Atrophy (SMA) China Registry

N/A

Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

Arthritis, Rheumatoid

N/A

Clinical Trials (1)

NCT01211678Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

N/A

A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects W

N/A

Clinical Trials (1)

NCT02778438A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

N/A

Tysabri

Spinocerebellar Ataxia Type 1

N/A

Clinical Trials (1)

NCT01071512Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

N/A

Instrumented Data Exchange for Ataxia Study

N/A

Clinical Trials (1)

NCT04268147Instrumented Data Exchange for Ataxia Study

N/A

Genomic Translation for Amyotrophic Lateral Sclerosis Care

ALS

N/A

Clinical Trials (1)

NCT02795897Genomic Translation for Amyotrophic Lateral Sclerosis Care

N/A

Psychometric Validation of Cognitive Endpoints